Pediatric intracranial ependymoma clinical trial

JRCT ID: jRCTs051180233

Registered date:30/03/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: intracranial ependymoma
• Date of first enrollment: 03/02/2017
• Target sample size: 40
• Study type: Interventional
• Intervention(s): Surgical resection, chemotherapy, radiotherapy

Outcome(s)

• Primary Outcome: Progression-free survival rate (PFS) in 2 years, 5 years, and 7 years
• Secondary Outcome: 2-year progression-free survival rate (PFS) and 2-year overall survival rate (OS) in each treatment group and histological gradings

Key inclusion & exclusion criteria

• Age minimum: >= 3age old
• Age maximum: < 20age old
• Gender: Both
• Include criteria: Newly developed intracranial ependymoma, from 3 years old to under 20 years old (no seeding metastatic lesions)

Exclude criteria

Exclude those subject to any of the following conditions.
1) Active duplication cancers (simultaneous duplicated cancers and metachronous duplicated cancers with disease-free period within 5 years).
2) Heart disease with treatment is merged.
3) Pregnant or lactating women
4) When judging that the doctor in charge is inappropriate

Related Information

• Primary Sponsor: Sakamoto Hiroaki
• Secondary Sponsor: Hara Junichi,Japan Agency for Medical Reserch and Development
• Secondary ID(s): UMIN000023803